Xellia Pharmaceuticals appoints Matthew Anderson as CFO

Xellia Pharmaceuticals, a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening infections, has further strengthened its leadership team by appointing Matthew Anderson as Chief Financial Officer (CFO) with immediate effect. He will be taking over from the current interim CFO, Otto Rasmussen.

Matthew brings over 20 years of corporate accounting and finance experience in international life science companies of various stages.

Commenting on his appointment as Xellia’s new CFO, Matthew Anderson said: “I am joining a dynamic leadership team at Xellia at a pivotal stage in the Company’s development. As well as getting on with the day-to-day financial operations, I look forward to working as part of the team to support the launch of new products and the expanded business operations in the US.”

Before Xellia, Matthew served as Chief Financial Officer, Vice President and Treasurer at PharMEDium Healthcare where he was responsible for all aspects of corporate accounting and finance. Prior to joining PharMEDium, he has held various positions of increasing leadership responsibility within the Medical Products and Services business of Cardinal Health, Inc.

He holds an MBA from Northwestern University Kellogg School of Management, a Master’s degree in Accountancy from DePaul University and Bachelor’s degree in Economics from Western Illinois University. He is also a Certified Public Accountant and Chartered Global Management Accountant.

Xellia is developing a pipeline of value-added anti-infective drugs that are centred on formulation improvements for marketed drugs from its core portfolio and is intended to enhance patient care.

The most advanced product in Xellia’s pipeline is its Novel Premixed Vancomycin Ready-to-Use (RTU) Bag. This product was recently granted Qualified Infectious Disease Product (QIDP) designation from the US Food & Drug Administration (FDA). QIDP provides incentives for the development of antibiotics, including priority review and eligibility for fast-track designation.

You may also like